Generic Name and Formulations:
Trimethoprim (as HCl) 50mg/5mL; bubble-gum flavored soln; alcohol- and dye-free.
Aytu BioScience, Inc.
Indications for PRIMSOL:
Susceptible acute otitis media (AOM) due to S. pneumoniae or H. influenzae in children. Susceptible initial episodes of uncomplicated UTIs in adults.
UTIs: 100mg twice daily, or 200mg once daily; both for 10 days. Renal dysfunction: CrCl 15–30mL/min: reduce dose by ½; CrCl <15mL/min: not recommended.
<6months: not recommended. ≥6months: AOM: 10mg/kg daily in 2 divided doses every 12 hours for 10 days. Renal dysfunction: CrCl 15–30mL/min: reduce dose by ½; CrCl <15mL/min: not recommended.
Megaloblastic anemia due to folate deficiency.
Avoid large doses or prolonged administration (increased risk of blood disorders). Monitor CBC, discontinue if signs of blood disorders occur. Possible folate deficiency (may give folate concomitantly). Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Folic acid inhibitor.
May potentiate phenytoin. May interfere with some creatinine tests (alkaline picrate reduction).
Rash, GI upset, hematological or renal effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline